Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:EVG NASDAQ:MTFB NASDAQ:ONC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVGEaton Vance Short Duration Diversified Income Fund$11.28-0.1%$11.11$10.25▼$11.45N/AN/A40,874 shs43,198 shsMTFBMotif Bio$0.11$0.10$0.08▼$11.50N/AN/AN/A867,698 shsONCBeOne Medicines$300.14-2.8%$281.26$170.99▼$330.63$32.90B0.27427,153 shs197,816 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVGEaton Vance Short Duration Diversified Income Fund+0.18%+0.22%+2.59%+5.02%+1.71%MTFBMotif Bio0.00%0.00%0.00%0.00%0.00%ONCBeOne Medicines+0.09%-1.15%+5.98%+28.49%+30,890,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEVGEaton Vance Short Duration Diversified Income FundN/AN/AN/AN/AN/AN/AN/AN/AMTFBMotif BioN/AN/AN/AN/AN/AN/AN/AN/AONCBeOne Medicines1.4165 of 5 stars2.50.00.00.02.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVGEaton Vance Short Duration Diversified Income Fund 0.00N/AN/AN/AMTFBMotif Bio 0.00N/AN/AN/AONCBeOne Medicines 3.00Buy$330.8910.24% UpsideCurrent Analyst Ratings BreakdownLatest ONC, EVG, MTFB, and BSFA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/7/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$349.00 ➝ $364.008/7/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$350.00 ➝ $365.007/17/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$321.00 ➝ $345.007/16/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$311.00 ➝ $349.006/27/2025ONCBeOne MedicinesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$313.00 ➝ $330.006/27/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$317.00 ➝ $321.006/27/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$311.00(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVGEaton Vance Short Duration Diversified Income Fund$13.65MN/AN/AN/AN/AN/AMTFBMotif BioN/AN/AN/AN/AN/AN/AONCBeOne Medicines$3.81B8.63N/AN/A$34.40 per share8.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVGEaton Vance Short Duration Diversified Income FundN/AN/A0.00∞N/AN/AN/AN/AN/AMTFBMotif BioN/AN/A0.00∞N/AN/AN/AN/AN/AONCBeOne Medicines-$644.79M-$1.73N/A422.73N/A-3.89%-1.22%-0.72%N/ALatest ONC, EVG, MTFB, and BSFA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025ONCBeOne Medicines$0.48$0.84+$0.36$0.84$1.24 billion$1.32 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVGEaton Vance Short Duration Diversified Income Fund$0.907.98%N/AN/AN/AMTFBMotif BioN/AN/AN/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/ALatest ONC, EVG, MTFB, and BSFA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/4/2025EVGEaton Vance Short Duration Diversified Income Fundmonthly$0.07438.2%8/15/20258/15/20258/29/20257/1/2025EVGEaton Vance Short Duration Diversified Income Fundmonthly$0.07438.2%7/15/20257/15/20257/31/20256/3/2025EVGEaton Vance Short Duration Diversified Income Fundmonthly$0.07378.5%6/16/20256/16/20256/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVGEaton Vance Short Duration Diversified Income FundN/AN/AN/AMTFBMotif BioN/AN/AN/AONCBeOne Medicines0.041.951.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVGEaton Vance Short Duration Diversified Income FundN/AMTFBMotif BioN/AONCBeOne Medicines48.55%Insider OwnershipCompanyInsider OwnershipEVGEaton Vance Short Duration Diversified Income FundN/AMTFBMotif BioN/AONCBeOne Medicines6.62%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVGEaton Vance Short Duration Diversified Income FundN/AN/AN/ANot OptionableMTFBMotif Bio7N/AN/ANot OptionableONCBeOne Medicines11,000109.60 million102.34 millionN/AONC, EVG, MTFB, and BSFA HeadlinesRecent News About These CompaniesBeOne Meds sells Imdelltra royalty for up to $950 millionAugust 26 at 4:01 PM | thepharmaletter.comTEC approves tablet formulation of BeOne Medicines’ BrukinsaAugust 26 at 6:53 AM | thepharmaletter.comTBeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare ConferenceAugust 26 at 6:01 AM | businesswire.comBeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-UpAugust 25 at 3:49 PM | finance.yahoo.comBeOne Medicines Announces $950 Million Royalty Purchase Agreement with Royalty Pharma for ImdelltraAugust 25 at 3:49 PM | pharmexec.comPRoyalty Pharma confirms acquisition of royalty interest in Amgen’s ImdelltraAugust 25 at 10:49 AM | msn.comBeOne bags $885M upfront in Royalty deal on Amgen's lung cancer drug ImdelltraAugust 25 at 10:49 AM | fiercepharma.comFBeOne Medicines to sell royalty rights of Imdelltra to Royalty Pharma for $950MAugust 25 at 10:49 AM | msn.comBeOne Medicines’ new film-coated tablet formulation of Brukinsa gets European nod for all approved indicationsAugust 23, 2025 | pharmabiz.comPBRUKINSA Tablet Approval Could Be a Game Changer for BeOne Medicines (ONC)August 22, 2025 | finance.yahoo.comBeOne Medicines’ Brukinsa tablet formulation approved by European CommissionAugust 21, 2025 | msn.comEuropean Commission Approves Tablet Formulation of BeOne Medicines' BRUKINSA® for All Approved IndicationsAugust 21, 2025 | businesswire.comInsider Selling: BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) COO Sells 39,936 Shares of StockAugust 18, 2025 | americanbankingnews.comBeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) SVP Sells $3,308,855.85 in StockAugust 17, 2025 | marketbeat.comXiaobin Wu Sells 39,936 Shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) StockAugust 17, 2025 | marketbeat.comBeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu Sells 49,858 SharesAugust 17, 2025 | marketbeat.comBeOne Medicines (NASDAQ:ONC) Reaches New 12-Month High - Time to Buy?August 17, 2025 | marketbeat.comInsider Selling: BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) SVP Sells 11,013 Shares of StockAugust 16, 2025 | insidertrades.comThis Medical Stock With Blockbuster Cancer Drug Clears Entry Amid 923% Earnings GrowthAugust 15, 2025 | investors.comBeOne Medicines posts 2nd-qtr revenue growth of 41%August 13, 2025 | thepharmaletter.comTStock Market Today: Dow Jones Index Rises While Nvidia-Backed CoreWeave Sinks On Earnings (Live Coverage)August 13, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025Tesla’s Pennant Just Snapped: Here’s What It Means for the StockBy Sam Quirke | August 14, 2025Apple Stock: Big Earnings, Small Move—Time to Buy?By Chris Markoch | August 1, 2025Alphabet Gains Momentum as Sentiment on Wall Street ImprovesBy Ryan Hasson | August 1, 2025ONC, EVG, MTFB, and BSFA Company DescriptionsEaton Vance Short Duration Diversified Income Fund NYSE:EVG$11.28 -0.02 (-0.13%) Closing price 03:58 PM EasternExtended Trading$11.14 -0.14 (-1.20%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eaton Vance Short Duration Diversified Income Fund is a closed ended fixed income mutual fund launched and managed by Eaton Vance Management. The fund invests in fixed income markets of the United States. It primarily invests in senior, secured floating-rate loans, bank deposits denominated in foreign currencies, debt obligations of foreign governmental and corporate issuers, and mortgage-backed securities. The fund invests in fixed income securities operating across diversified sectors. It invests in fixed income securities with an average duration of 1.76 years and an average credit quality of least BBB. The fund benchmarks the performance of its portfolio against the S&P/LSTA Leveraged Loan Index. It was formerly known as Eaton Vance Low Duration Diversified Income Fund. Eaton Vance Short Duration Diversified Income Fund was formed on February 28, 2005 and is domiciled in the United States.Motif Bio NASDAQ:MTFBMotif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.BeOne Medicines NASDAQ:ONC$300.14 -8.77 (-2.84%) As of 04:00 PM EasternBeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Williams-Sonoma Q2 Results Prove Its Buy-and-Hold Quality Okta: Market Comes to a Boil, Explosive Upside Is Possible MongoDB Roars Back to Life: It’s Not Too Late to Buy More Vertical Aerospace: An Analyst's Roadmap to a Potential Re-Rating AEHR Spikes 36% on Hyperscaler Order—Investors Should Take Notice From Debt to Liftoff: EchoStar's $23 Billion Catalyst Buffett’s Wisdom Could Spell Trouble for Palantir Shorts Tesla Just Had Its Best Day in 2 Months—Here’s What It Means Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access